

Online supplementary Table S1 Differences between empagliflozin and dapagliflozin allocated patients across baseline characteristics.

Baseline Characteristic	Empagliflozin	Dapagliflozin	Empagliflozin vs. dapagliflozin p value
Age (years)	60.25 ± 8.83	64.3 ± 8.16	0.58
Type 2 diabetes duration (years)	9.18 ± 6.28	10 ± 6.5	0.65
Body mass index (kg/m²)	32.73 ± 5.52	32.6 ± 5.89	0.69
Glycated hemoglobin (%)	7.69 ± 1.77	7.36 ± 1.37	0.65
Cardiovascular disease	9 (56.25%)	17 (56.67%)	0.17
Hypertension	12 (75%)	20 (66.67%)	0.61
Coronary artery disease	5 (31.25%)	9 (30%)	0.35
Heart failure	1 (6.25%)	4 (13.33%)	0.12
Cerebrovascul ar disease	2 (12.5%)	5 (16.67%)	0.99
Dyslipidemia	12 (75%)	16 (53.33%)	0.37
Metformin	15 (93.75%)	28 (93.33%)	0.52
Insulin	6 (37.5%)	7 (23.33%)	0.29
GLP-1 receptor agonists	7 (43.75%)	8 (26.67%)	0.99
DPP-4 inhibitors	6 (37.5%)	12 (40%)	0.64
Sulphonylureas	3 (18.75%)	3 (10%)	0.009
RAAS blockers	12 (75%)	17 (56.67%)	0.61
Calcium channel blockers	5 (31.25%)	8 (26.67%)	0.99
Diuretics	4 (25%)	14 (46.67%)	0.99
B-blockers	7 (43.75%)	11 (36.67%)	0.64
Antiplatelet agents	11 (68.75%)	13 (43.33%)	0.33

Statins	14 (87.5%)	17 (56.67%)	0.052
----------------	------------	-------------	-------